|
Company Name: Stem Cell Sciences (SCS)
Company Type: Research
Company Profile
6 September 2006
Stem Cell Sciences is awarded Small/Mid-Size Company Deal of the Year by
Scottish Business Insider Deals & Dealmakers for the floatation of SCS plc on
the London Stock Exchange Alternative Investment Market (AIM: STEM)
29 August 2006
SCS is one of only three commercial partners in the €12 million ESTOOLS
project
25 July 2006
SCS plc in-licensing of hMADS technology for drug screening applications
12 December 2005
Selected as a Technology Pioneer in Biotechnology by the World Economic Forum
for SCS' Selection Technology which allows purification of human stem cells on
the basis of any differentially expressed gene
22 November 2005
Awarded ‘Business Leader' in the field of Stem Cells in the 2005 Scientific
American 50
6 October 2005
First commercial products, ESGRO Complete™ product line, licensed to Chemicon
(now part of Millipore Corporation) as the first commercially available
serum-free and feeder-free mouse Embryonic Stem cell medium
13 July 2005
Successful IPO and Admission to the London Stock Exchange Alternative Investment
Market (AIM: STEM), raising £6.02m
18 February 2005
Australia expands into new stem cell facility and releases MEL-1 and MEL-2 human
ES cell lines
31 January 2005
SCS led consortium secures £1.22 million in DTI funding to develop the use of ES
cells in high-throughput assays
About Company
Who:
Stem Cell Sciences (SCS) is an international research and development
company specialising in the provision of stem cells and stem cell technologies
for research and the clinic.
SCS takes pride in its long-standing relationships with leading academic centres
of excellence in the stem cell field, which help maintain the Company’s position
at the cutting edge of the stem cell industry.
Stem Cell Sciences has an established track record of commercialisation with
international biotechnology and pharmaceutical companies including Pfizer,
Sanofi-Aventis, GSK, Chemicon, Deltagen and Lexicon.
What:
Stem Cell Sciences has been active in the stem cell research field since 1994,
principally focused on technologies to grow, differentiate, and purify embryonic
and neural stem cells. The Company now has a substantial portfolio of patents
and patent applications in both adult and embryonic stem cell fields. These
include technologies to permit the generation of highly purified stem cells and
their differentiated progeny for use in genetic, pharmacological and
toxicological screens. Moreover, these technologies can be utilised to provide
pure populations of appropriate cell types for transplantation therapies.
Why:
Stem Cell Sciences’ core objective is to develop safe and effective stem
cell-based therapies for currently incurable diseases.
Where:
We have business and scientific operations in Edinburgh and Cambridge (UK),
Melbourne (Australia) and Kobe (Japan). In 2007 SCS will open new offices in
California (USA).
| Address: |
30 Farringdon Street, London, EC4A 4HJ |
City: London State:: London |
| Contact: |
|
Phone: +44 (0)131 662 9829 Fax:: +44 (0)131 662 9779 |
| Website: |
http://www.stemcellsciences.com |
Email: |
| Registered: |
24 June, 2007 09:31 |
| Company Products: |
ESGRO Complete™ Clonal Grade Medium, HEScGRO Medium for Human ES Cell Culture, NDiff™ N2B27 (beta), NDiff™ Neuro-2 Medium Supplement (200x), NDiff™ Neuro-27 Medium Supplement (100x), NDiff™ RHB-A™ (beta) |
| Related Company: |
Bruker BioSpin Corp, CABI, Earthquake Engineering Research Institute, Foundation for Biomedical Research, Indian Agribusiness Systems Pvt. Ltd., Institute of Materials Science and Technology, Linear Systems Ltd., LumaSense Technologies, Microfluidics International Corporation, NanoMarkets, LC, Organic Farming Research Foundation, Pacific Nanotechnology, Rosetta Genomics, Ltd., Taizhou Warmtry Yeguangming Industrial Co., Ltd., Tepha Inc., The National Address Server, University of Southampton |
|
